The Global Stomach Cancer Drugs Market size was valued at USD 4.7 billion in 2018 and is anticipated to grow at a CAGR of 6.1% during the forecast period. Gastric cancer is also known as stomach cancer, and it is characterized by the growth of cancerous cells within the lining of the stomach. Stomach cancer is a relatively rare type of cancer. Some of the risk factors associated with stomach cancer are lymphoma, H. pylori bacterial infections, tumors in other parts of the digestive system, and stomach polyps.
Stomach Cancer Drugs Market Statistics
The growing elderly population, technological advancement and rising incidence and prevalence rate of stomach cancer are boosting the abdomen cancer market across the world. Stomach cancer leads to uncontrolled progress of malignant cells that originate in abdomen tissue. the main cause for the developing abdomen cancer is still not known exactly, but bacterium Helicobacter Pylori is one of the key causes and also Smoking & ulcer are some factors leading to abdomen cancer. Other factors included age, diet, and stomach disease can affect the risk of developing stomach cancer. Approx. 800,000 cancer connected death are causes by stomach cancer every year, as per the World Health Organization.
Key Factors Impacting the Growth of Stomach Cancer Drugs Market:
- Emerging research, developmental studies, and clinical trials to understand abdomen cancer higher and to develop medication are highly contributing to the stomach cancer drugs market revenue.
- Approval from FDA (Food and Drug Association) for biosimilars, is likely to expand the stomach cancer drugs market.
The stomach cancer drugs market segmentation is based on drugs, devices, route of administration, and region.
Stomach Cancer Drugs Market Segmentation
Therapy Outlook:
Based on the therapy segment, the chemotherapy segment is expected to register the highest CAGR during the forecast period. The chemotherapy segment is the most typical type of medicine accustomed to stop or slows the expansion of cancer cells. Surgery and radiation therapy works by removing, killing, or damaging the cancer cells in a certain space, while chemotherapy works throughout the whole body.
Application Outlook:
On the basis of application type, the market is segmented into Adenocarcinomas, Gastrointestinal Stromal Tumors, Carcinoid Tumor.
End User Outlook:
On the basis of end user, the global stomach cancer drugs market is classified as hospitals, clinics, specialized cancer treatment centers, and ambulatory surgical centers. Among the end user, hospitals and specialized cancer treatment centers segments together account a maximum share of the global market.
Stomach Cancer Drugs Market Regional Analysis
Regional Outlook:
Based on the region, the global stomach cancer drugs market has been segmented by North America, Western Europe, Eastern Europe, Asia Pacific, Middle East, and Rest of the World. In terms of revenue, Asia-Pacific holds a dominant position in the global stomach cancer drugs market in 2018 owing to the increasing incidence and prevalence of stomach cancer in the region. Also, more than 60% of the world's gastric cancer cases are from rising economies such as South Korea, China, Japan, and India. Growing disposable income, awareness and health care spending will further drive the gastric cancer testing market in the APAC region. China and Japan have the largest drug market share in terms of the large patient base and rise in the treatment-seeking population in these regions. The gastric cancer drug market in North America and Europe rising strongly in the uptake of gastric cancer drugs specifically herceptin, erbitux and afinitor also emphasizes the growth of these drugs.
Competitive Landscape
The increasing number of obesity cases and smoking populations increased the number of people suffering from gastric cancer. Consuming tobacco and following diet unhealthy diet increases the risk of stomach cancer. The key leading players in the market include Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline Plc., Kuhnil Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Merck KGaA, AstraZeneca Plc, Otsuka Holdings Co. Ltd., Sanofi S.A., and F. Hoffmann-La Roche Ltd, Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb (BMS), Jiangsu HengRui Medicine Co. Ltd., Gilead Science Inc., Celgene Corporation, Taiho Pharmaceutical, Boston Biomedical Inc., and Merck & Co.
This report also includes the profiles of key stomach cancer drugs market companies along with their SWOT analysis and market strategies. In addition, these competitive landscapes provide a detailed description of each company including future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launch, new product developments, and other latest industrial developments.
Key Developments in Stomach Cancer Drugs Market:
- In April 2019, AstraZeneca, a multinational pharmaceutical and biopharmaceutical company acquired Daiichi Sankyo for $1.35 billion. This acquisition will help AstraZeneca to jointly develop drug Trastuzumab Deruxtecan with Daiichi Sankyo. This drug would help to treat people suffering from breast and gastric cancer. Daiichi Sankyo headquartered in Japan is a global pharmaceutical company which offers innovative products and a robust pipeline for cancer treatment.·
- In January 2019, the U.S. FDA approved South Korea’s Samsung Bioepis’ Ontruzant (trastuzumab biosimilar) for the treatment of metastatic gastric cancer or gastro-esophageal junction adenocarcinoma. Samsung Bioepis is a joint venture between Samsung Biologics and Biogen. The biosimilar was approved by the European Commission (EC) in November 2017.·
- In October 2016, Teva Pharmaceuticals partnered with Celltrion Healthcare Co. Ltd to commercialize biosimilar versions of Roche’s Herceptin to strengthen its product portfolio and fill a gap in its biosimilars pipeline.
Stomach Cancer Drugs Market Timeline(2017-2028)
What Does This Report Provide?
This report provides a detailed understanding of the global stomach cancer drugs market from qualitative and quantitative perspectives during the forecast period. The report also provides dynamic indicators with potential impact on the market during the forecast period and an in-depth analysis of the leading companies operating in the market.
Market Segmentation:
By Therapy
- Surgery
- Chemotherapy
- Targeted Theory
- Immunotherapy
- Radiation Therapy
By End- User
- Hospitals
- Clinics
- Specialized Cancer Centers
- Ambulatory Surgical Centers
By Route Of Application
- Adenocarcinomas
- Gastrointestinal Stromal Tumor
- Carcinoid Tumors
By Region:
- North America
- By Country (US, Canada, Mexico)
- By Therapy
- By Application
- By End User
- Western Europe
- By Country (Germany, UK, France, Italy, Spain, Rest of Western Europe)
- By Therapy
- By Application
- By End User
- Eastern Europe
- By Country (Russia, Turkey, Rest of Eastern Europe)
- By Therapy
- By Application
- By End User
- Asia Pacific
- By Country (China, Japan, India, South Korea, Australia, Rest of Asia Pacific)
- By Therapy
- By Application
- By End User
- Middle East
- By Country (UAE, Saudi Arabia, Qatar, Iran, Rest of Middle East)
- By Therapy
- By Application
- By End User
- Rest of the World
- By Region (South America, Africa)
- By Therapy
- By Application
- By End User
Reasons to Buy This Report:
- Market size estimation of the stomach cancer drugs market on a regional and global basis
- Unique research Usage for market size estimation and forecast
- Profiling of major companies operating in the market with key developments
- Broad scope to cover all the possible segments helping every stakeholder in the market
Customization:
We provide customization of the study to meet specific requirements:
- By Segment
- By Sub-segment
- By Region/Country
For more information, contact: sales@quincemarketinsights.com